Adaptimmune Therapeutics Plc ADAP 股票预测
Adaptimmune Therapeutics Plc的AI驱动价格预测与分析 · 已更新 十一月 21, 2025
AI 90天预测
持有
7天
30天
90天
AI置信度: 39% 斯皮尔曼相关性
十一月 21, 2025
价格图表
正在加载图表...
关键统计数据
市值
$77M
市盈率
-13.2x
市净率
-11.77x
每股收益
$-0.11
净利率
-533.8%
收入
$65M
关于 Adaptimmune Therapeutics Plc
Adaptimmune Therapeutics Plc (ADAP) 在Life Sciences行业运营，具体属于Biological Products, (No Diagnostic Substances)业务. .
Adaptimmune is a biopharmaceutical company that develops T cell therapies against cancer. The company was founded in 2008 in the UK with links to both Oxford University and the University of Pennsylvania. It has headquarters in Philadelphia and Milton Park. In August 2024, the US Food and Drug Administration granted accelerated approval to Adaptimmune's Tecelra, a therapy against a rare form of cancer. Tecelra is the first T cell therapy to be approved for use against a solid tumor. In …
最新新闻
Biological Products, (No Diagnostic Substances) 同行公司
| 公司 | 股票代码 | AI信号 | 市值 | 市盈率 |
|---|---|---|---|---|
| Acumen Pharmaceuticals, Inc. | ABOS | ██% | $185M | -x |
| Abpro Holdings, Inc. | ABP | ██% | $310K | -x |
| Abpro Holdings, Inc. | ABPO | ██% | $870K | -x |
| Arcellx, Inc. | ACLX | ██% | $6.73B | -x |
| Alpha Cognition Inc. | ACOG | ██% | $133M | -x |
| Adaptimmune Therapeutics Plc | ADAP | ██% | $77M | -13.2x |
| Adma Biologics, Inc. | ADMA | ██% | $1.90B | 11.5x |
| Adaptive Biotechnologies Corp | ADPT | ██% | $2.21B | -x |
| Adverum Biotechnologies, Inc. | ADVM | ██% | $95M | -1.8x |
| Agenus Inc | AGEN | ██% | $159M | 1379.8x |
| Agentix Corp. | AGTX | ██% | $2M | -x |
| Aim Immunotech Inc. | AIM | ██% | $3M | -x |
| Aim Immunotech Inc. | AIMI | ██% | $1M | -x |
| Alector, Inc. | ALEC | ██% | $233M | -x |
| Aligos Therapeutics, Inc. | ALGS | ██% | $40M | -x |
| Allogene Therapeutics, Inc. | ALLO | ██% | $787M | -x |
| Alvotech | ALVO | ██% | $1.02B | -x |
| Amgen Inc | AMGN | ██% | $179.02B | 23.0x |
| Apogee Therapeutics, Inc. | APGE | ██% | $5.68B | -x |
| Aptose Biosciences Inc. | APTOF | ██% | $4M | -x |
| Argenx Se | ARGX | ██% | $48.40B | -x |
| Armata Pharmaceuticals, Inc. | ARMP | ██% | $305M | -x |
| Artiva Biotherapeutics, Inc. | ARTV | ██% | $269M | -x |
| Leonabio, Inc. | ATHA | ██% | $23M | -0.2x |
| Atara Biotherapeutics, Inc. | ATRA | ██% | $71M | 2.2x |
| Atyr Pharma Inc | ATYR | ██% | $93M | -x |
| Aura Biosciences, Inc. | AURA | ██% | $927M | -x |
| Autolus Therapeutics Plc | AUTL | ██% | $418M | -x |
| Anavex Life Sciences … | AVXL | ██% | $298M | -x |
| Bioatla, Inc. | BCAB | ██% | $8M | -x |
| Biocardia, Inc. | BCDA | ██% | $12M | -x |
| Brainstorm Cell Therapeutics … | BCLI | ██% | $8M | -x |
| Biocryst Pharmaceuticals Inc | BCRX | ██% | $2.19B | -x |
| Black Diamond Therapeutics, … | BDTX | ██% | $171M | -x |
| Beam Therapeutics Inc. | BEAM | ██% | $3.32B | -x |
| Biogen Inc. | BIIB | ██% | $28.48B | 20.8x |
| Biontech Se | BNTX | ██% | $23.80B | -x |
| Cabaletta Bio, Inc. | CABA | ██% | $633M | -x |
| Candel Therapeutics, Inc. | CADL | ██% | $612M | -x |
| C4 Therapeutics, Inc. | CCCC | ██% | $325M | -x |
| Cidara Therapeutics, Inc. | CDTX | ██% | $6.49B | -1.0x |
| Creative Medical Technology … | CELZ | ██% | $9M | -x |
| Cero Therapeutics Holdings, … | CERO | ██% | $1M | -x |
| Cullinan Therapeutics, Inc. | CGEM | ██% | $894M | -x |
| Compugen Ltd | CGEN | ██% | $274M | 3.9x |
| Cg Oncology, Inc. | CGON | ██% | $6.13B | -x |
| Cognition Therapeutics Inc | CGTX | ██% | $108M | -x |
| Coherus Oncology, Inc. | CHRS | ██% | $262M | 1.6x |
| Calidi Biotherapeutics, Inc. | CLDI | ██% | $3M | -x |
| Cellectis S.A. | CLLS | ██% | $387M | -x |
| Compass Therapeutics, Inc. | CMPX | ██% | $330M | -x |
| Mosaic Immunoengineering Inc. | CPMV | ██% | $2M | -x |
| Caribou Biosciences, Inc. | CRBU | ██% | $142M | -1.5x |
| Cardiff Oncology, Inc. | CRDF | ██% | $112M | -x |
| Cardiol Therapeutics Inc. | CRDL | ██% | $147M | -x |
| Curis Inc | CRIS | ██% | $22M | -x |
| Crispr Therapeutics Ag | CRSP | ██% | $5.28B | -x |
| Champions Oncology, Inc. | CSBR | ██% | $84M | -x |
| Cel Sci Corp | CVM | ██% | $14M | -x |
| Dbv Technologies S.A. | DBVT | ██% | $1.17B | -x |
| Dbv Technologies S.A. | DBVTF | ██% | $10K | -x |
| Ginkgo Bioworks Holdings, … | DNA | ██% | $551M | -x |
| Denali Therapeutics Inc. | DNLI | ██% | $3.11B | -x |
| Precision Biosciences Inc | DTIL | ██% | $198M | -x |
| Dyadic International Inc | DYAI | ██% | $28M | -x |
| Editas Medicine, Inc. | EDIT | ██% | $304M | -x |
| Eloxx Pharmaceuticals, Inc. | ELOX | ██% | $990K | -x |
| Elutia Inc. | ELUT | ██% | $47M | 0.9x |
| Engene Therapeutics Inc. | ENGN | ██% | $100M | -x |
| Entera Bio Ltd. | ENTX | ██% | $71M | -x |
| Viskase Holdings, Inc. | ENZN | ██% | $40M | -x |
| Estrella Immunopharma, Inc. | ESLA | ██% | $54M | -x |
| Evaxion A/S | EVAX | ██% | $36M | -x |
| Exelixis, Inc. | EXEL | ██% | $12.22B | 14.7x |
| Exozymes Inc. | EXOZ | ██% | $81M | -x |
| Fate Therapeutics Inc | FATE | ██% | $276M | -x |
| 4d Molecular Therapeutics, … | FDMT | ██% | $530M | -x |
| Fennec Pharmaceuticals Inc. | FENC | ██% | $237M | -x |
| Finch Therapeutics Group, … | FNCH | ██% | $12M | 0.5x |
| Finch Therapeutics Group, … | FNCHQ | ██% | $13M | 0.5x |
| Futuretech Ii Acquisition … | FTII | ██% | $52M | -x |
| Futuretech Ii Acquisition … | FTIIU | ██% | $14M | -x |
| Gilead Sciences, Inc. | GILD | ██% | $163.11B | 17.7x |
| Monte Rosa Therapeutics, … | GLUE | ██% | $1.64B | -x |
| Genenta Science S.P.A. | GNTA | ██% | $15M | -x |
| Green Planet Bio … | GPLB | ██% | $340K | -x |
| Greenland Mines Ltd | GRML | ██% | $56M | -x |
| Halozyme Therapeutics, Inc. | HALO | ██% | $7.55B | 23.8x |
| Humacyte, Inc. | HUMA | ██% | $235M | -x |
| Immunitybio, Inc. | IBRX | ██% | $8.91B | -x |
| Inhibikase Therapeutics, Inc. | IKT | ██% | $272M | -x |
| Imagenebio, Inc. | IMA | ██% | $60M | -x |
| Immunocore Holdings Plc | IMCR | ██% | $1.50B | -x |
| Immatics N.V. | IMTX | ██% | $1.52B | -x |
| Immunovant, Inc. | IMVT | ██% | $5.88B | -x |
| In8bio, Inc. | INAB | ██% | $16M | -x |
| Inhibrx Biosciences, Inc. | INBX | ██% | $873M | -6.8x |
| Mink Therapeutics, Inc. | INKT | ██% | $55M | -x |
| Inmune Bio, Inc. | INMB | ██% | $38M | -x |
| Intensity Therapeutics, Inc. | INTS | ██% | $13M | -x |
| Iovance Biotherapeutics, Inc. | IOVA | ██% | $1.59B | -x |
| Century Therapeutics, Inc. | IPSC | ██% | $413M | -x |
| Invivyd, Inc. | IVVD | ██% | $423M | -x |
| Jasper Therapeutics, Inc. | JSPR | ██% | $26M | -x |
| Kalaris Therapeutics, Inc. | KLRS | ██% | $116M | -x |
| Klotho Neurosciences, Inc. | KLTO | ██% | $56M | -x |
| Kodiak Sciences Inc. | KOD | ██% | $2.55B | -x |
| Krystal Biotech, Inc. | KRYS | ██% | $9.00B | 40.0x |
| Kymera Therapeutics, Inc. | KYMR | ██% | $7.07B | -x |
| Kyverna Therapeutics, Inc. | KYTX | ██% | $565M | -x |
| Ladrx Corp | LADX | ██% | $20K | -x |
| Lineage Cell Therapeutics, … | LCTX | ██% | $333M | -x |
| Lenz Therapeutics, Inc. | LENZ | ██% | $315M | -x |
| Atyr Pharma Inc | LIFE | ██% | $1.87B | -x |
| Liminatus Pharma, Inc. | LIMN | ██% | $9M | -x |
| Leonabio, Inc. | LONA | ██% | $94M | -x |
| Lexeo Therapeutics, Inc. | LXEO | ██% | $426M | -x |
| Maze Therapeutics, Inc. | MAZE | ██% | $1.44B | -x |
| Mesoblast Ltd | MESO | ██% | $1.91B | -x |
| Meiragtx Holdings Plc | MGTX | ██% | $909M | -x |
| Metagenomi Therapeutics, Inc. | MGX | ██% | $53M | -x |
| Molecular Partners Ag | MOLN | ██% | $166M | -x |
| Moderna, Inc. | MRNA | ██% | $21.58B | -x |
| Neurocrine Biosciences Inc | NBIX | ██% | $15.32B | 22.9x |
| Nkgen Biotech, Inc. | NKGN | ██% | $2M | -0.1x |
| Neumora Therapeutics, Inc. | NMRA | ██% | $329M | -x |
| Novavax Inc | NVAX | ██% | $1.66B | -x |
| Ocugen, Inc. | OCGN | ██% | $511M | -x |
| Outlook Therapeutics, Inc. | OTLK | ██% | $27M | -x |
| Palisade Bio, Inc. | PALI | ██% | $302M | -x |
| Passage Bio, Inc. | PASG | ██% | $13M | -x |
| Vaxcyte, Inc. | PCVX | ██% | $7.65B | -x |
| Biomx Inc. | PHGE | ██% | $6M | -x |
| Pluri Inc. | PLUR | ██% | $35M | -x |
| Protalix Biotherapeutics, Inc. | PLX | ██% | $156M | -x |
| Pharmacyte Biotech, Inc. | PMCB | ██% | $8M | -x |
| Prime Medicine, Inc. | PRME | ██% | $580M | -x |
| Prokidney Corp. | PROK | ██% | $562M | -x |
| Pelthos Therapeutics Inc. | PTHS | ██% | $82M | -x |
| Qiagen N.V. | QGEN | ██% | $7.17B | -x |
| Quince Therapeutics, Inc. | QNCX | ██% | $21M | -x |
| Qrons Inc. | QRON | ██% | $150K | -x |
| Replimune Group, Inc. | REPL | ██% | $324M | -x |
| Repligen Corp | RGEN | ██% | $6.96B | 135.5x |
| Regenxbio Inc. | RGNX | ██% | $537M | -x |
| Relay Therapeutics, Inc. | RLAY | ██% | $2.41B | -x |
| Revolution Medicines, Inc. | RVMD | ██% | $28.39B | -x |
| Recursion Pharmaceuticals, Inc. | RXRX | ██% | $1.76B | -x |
| Sab Biotherapeutics, Inc. | SABS | ██% | $289M | 21.8x |
| Sana Biotechnology, Inc. | SANA | ██% | $936M | -x |
| Scilex Holding Co | SCLX | ██% | $55M | -x |
| Scinai Immunotherapeutics Ltd. | SCNI | ██% | $2M | -x |
| Sangamo Therapeutics, Inc | SGMO | ██% | $50M | -x |
| Solid Biosciences Inc. | SLDB | ██% | $715M | -x |
| Silexion Therapeutics Corp | SLXN | ██% | $2M | -x |
| Senti Biosciences, Inc. | SNTI | ██% | $31M | -x |
| Scholar Rock Holding … | SRRK | ██% | $5.76B | -x |
| Surrozen, Inc./De | SRZN | ██% | $333M | -x |
| Sutro Biopharma, Inc. | STRO | ██% | $667M | -x |
| Protara Therapeutics, Inc. | TARA | ██% | $282M | -x |
| Tarsus Pharmaceuticals, Inc. | TARS | ██% | $2.63B | -x |
| Tc Biopharm (Holdings) … | TCBPY | ██% | $10K | -x |
| Tscan Therapeutics, Inc. | TCRX | ██% | $82M | -x |
| Bio-Techne Corp | TECH | ██% | $7.57B | 69.1x |
| Tectonic Therapeutic, Inc. | TECX | ██% | $546M | -x |
| Instil Bio, Inc. | TIL | ██% | $55M | -x |
| Tenaya Therapeutics, Inc. | TNYA | ██% | $217M | -x |
| Tourmaline Bio, Inc. | TRML | ██% | $1.23B | -3.5x |
| Taysha Gene Therapies, … | TSHA | ██% | $1.96B | -x |
| Titan Pharmaceuticals Inc | TTNP | ██% | $6M | -0.5x |
| Tevogen Bio Holdings … | TVGN | ██% | $29M | -x |
| Twist Bioscience Corp | TWST | ██% | $3.53B | -x |
| Voyager Acquisition Corp./Cayman … | VACH | ██% | $399M | 44.4x |
| Voyager Acquisition Corp./Cayman … | VACHU | ██% | $68M | 6.7x |
| Valneva Se | VALN | ██% | $534M | -x |
| Vericel Corp | VCEL | ██% | $1.63B | 76.0x |
| Vir Biotechnology, Inc. | VIR | ██% | $1.51B | -x |
| Vivosim Labs, Inc. | VIVS | ██% | $4M | -x |
| Vor Biopharma Inc. | VOR | ██% | $916M | -x |
| Vaxart, Inc. | VXRT | ██% | $169M | 4.6x |
| Voyager Therapeutics, Inc. | VYGR | ██% | $253M | -x |
| Windtree Therapeutics Inc … | WINT | ██% | $620K | -x |
| X4 Pharmaceuticals, Inc | XFOR | ██% | $419M | -x |
| Zeo Scientifix, Inc. | ZEOX | ██% | $15M | -x |
| Zivo Bioscience, Inc. | ZIVO | ██% | $15M | -x |
| Zura Bio Ltd | ZURA | ██% | $432M | -x |
常见问题
-
Adaptimmune Therapeutics Plc是值得买入的好股票吗？
我们的AI每天分析Adaptimmune Therapeutics Plc。查看上方信号获取最新建议。投资前请务必自行研究。
-
Adaptimmune Therapeutics Plc的预测有多准确？
我们的AI在该股票的斯皮尔曼相关性达到39%，每天分析的4,000+只股票中平均准确率超过67%。
-
预测多久更新一次？
Adaptimmune Therapeutics Plc的预测使用最新市场数据和AI模型每天更新。
想要Adaptimmune Therapeutics Plc的更深入分析吗？
在Intratio上查看完整的机构级分析 →AI预测基于历史模式，不应作为投资决策的唯一依据。过往表现不保证未来结果。请务必自行研究。